[{"id":"bedbd783-08c6-45af-8549-e837e9ef10ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT07198620","created_at":"2025-10-04T08:02:50.601Z","updated_at":"2025-10-04T08:02:50.601Z","phase":"","brief_title":"A Real-World Study of IBI351 for KRAS G12C+ NSCLC in China","source_id_and_acronym":"NCT07198620","lead_sponsor":"Guangdong Association of Clinical Trials","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Dupert (fulzerasib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 10/01/2025","start_date":" 10/01/2025","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-09-30"},{"id":"4edb91dd-56f6-4776-8ade-72d175e4050b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05756153","created_at":"2023-03-06T15:01:50.513Z","updated_at":"2024-07-02T16:35:15.394Z","phase":"Phase 1/2","brief_title":"A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation","source_id_and_acronym":"NCT05756153","lead_sponsor":"Zhejiang Genfleet Therapeutics Co., Ltd.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Dupert (fulzerasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 04/25/2023","start_date":" 04/25/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-03-11"},{"id":"a339e4f0-dcc9-4e6e-8f2e-c32e50e4a630","acronym":"","url":"https://clinicaltrials.gov/study/NCT05005234","created_at":"2021-08-13T12:53:37.125Z","updated_at":"2024-07-02T16:35:39.892Z","phase":"Phase 1/2","brief_title":"A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations","source_id_and_acronym":"NCT05005234","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Dupert (fulzerasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 264","initiation":"Initiation: 09/10/2021","start_date":" 09/10/2021","primary_txt":" Primary completion: 01/10/2024","primary_completion_date":" 01/10/2024","study_txt":" Completion: 04/10/2024","study_completion_date":" 04/10/2024","last_update_posted":"2023-08-16"},{"id":"20721144-e9cd-453f-b92b-1a2a17a1cf25","acronym":"","url":"https://clinicaltrials.gov/study/NCT05504278","created_at":"2022-08-17T13:55:02.248Z","updated_at":"2024-07-02T16:35:46.947Z","phase":"Phase 1","brief_title":"Efficacy and Safety of IBI351 in Combination With Sintilimab ± Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation","source_id_and_acronym":"NCT05504278","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • carboplatin • Tyvyt (sintilimab) • pemetrexed • Dupert (fulzerasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 144","initiation":"Initiation: 09/20/2022","start_date":" 09/20/2022","primary_txt":" Primary completion: 05/12/2024","primary_completion_date":" 05/12/2024","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2023-05-29"},{"id":"23218a61-aa25-45a3-9e9b-a24cae599c83","acronym":"","url":"https://clinicaltrials.gov/study/NCT05497336","created_at":"2022-08-22T09:59:55.647Z","updated_at":"2024-07-02T16:36:03.127Z","phase":"Phase 1","brief_title":"A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05497336","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Dupert (fulzerasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 08/18/2022","start_date":" 08/18/2022","primary_txt":" Primary completion: 08/30/2023","primary_completion_date":" 08/30/2023","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2022-09-30"}]